Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Chubb
UBS
Federal Trade Commission
Baxter
Daiichi Sankyo
Fuji
Farmers Insurance
Boehringer Ingelheim

Generated: January 23, 2018

DrugPatentWatch Database Preview

OMNICEF Drug Profile

« Back to Dashboard

When do Omnicef patents expire, and when can generic versions of Omnicef launch?

Omnicef is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in OMNICEF is cefdinir. There are twelve drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the cefdinir profile page.

US Patents and Regulatory Information for OMNICEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie OMNICEF cefdinir CAPSULE;ORAL 050739-001 Dec 4, 1997 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie OMNICEF cefdinir FOR SUSPENSION;ORAL 050749-001 Dec 4, 1997 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Abbvie OMNICEF cefdinir FOR SUSPENSION;ORAL 050749-002 Jul 29, 2004 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for OMNICEF

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie OMNICEF cefdinir CAPSULE;ORAL 050739-001 Dec 4, 1997 ➤ Subscribe ➤ Subscribe
Abbvie OMNICEF cefdinir FOR SUSPENSION;ORAL 050749-001 Dec 4, 1997 ➤ Subscribe ➤ Subscribe
Abbvie OMNICEF cefdinir FOR SUSPENSION;ORAL 050749-002 Jul 29, 2004 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Harvard Business School
Argus Health
US Army
Baxter
Citi
US Department of Justice
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot